Cambridge / London (dpa-AFX) – Astrazeneca . pharmaceutical company
He is considering an initial public offering, according to insiders, for his new section on vaccines and immunotherapies. Management is at an early stage to explore the division’s best lineup, Bloomberg News wrote Friday night, citing people familiar with the matter. In addition to other options, external advisors have also been discussed about going public with the company’s shares in order to create more value for shareholders. CEO Pascal Soriot has been under pressure from investors for a long time due to the slow development of prices compared to the competition.
AstraZeneca recently announced the creation of its Vaccines & Antibody Therapeutics division. In November, the British-Swedish company also announced that it no longer wanted to sell its coronavirus vaccine at cost. It was said that many profit-making agreements have been signed for 2022. This is how competitors achieve Pfizer / Biontech as well as our modern High profits with their vaccines. / mis/ck
ISIN GB0009895292
AXC0298 2021-12-03 / 19:10
Copyright dpa-AFX Wirtschaftsnachrichten GmbH. All rights reserved. No redistribution, republication or permanent storage is permitted without the prior express consent of dpa-AFX.
More Stories
GenAI in everyday work – Top management is moving forward with AI, employees are hesitant » Leadersnet
Foreign Exchange: Euro rises against the dollar
Lufthansa Group: Austrian Airlines, the Boeing 737 MAX and the cargo problem